110 results
8-K
EX-99.1
OVID
Ovid Therapeutics Inc
14 May 24
Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results
8:03am
, double-blind, multiple-ascending dose trial evaluating OV888 (GV101) is complete; topline safety data are expected in H1 2024
Ovid expects to initiate … (GV101): Ovid and its collaborator, Graviton Bioscience, have completed a Phase 1 multiple-ascending dose (MAD) study of OV888 (GV101), with topline safety
8-K
EX-99.1
OVID
Ovid Therapeutics Inc
8 Mar 24
Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results
8:20am
for the potential treatment of CCM and other rare neurological conditions. Ovid and Graviton Bioscience expect to initiate a Phase 2 efficacy and safety … treatment of chronic seizures is being actively evaluated in a Phase 1 safety study, which includes surrogate biomarkers to measure target engagement
424B5
pvgzx55 0j
15 Nov 23
Prospectus supplement for primary offering
4:11pm
8-K
EX-99.1
ox72ghg1xz
3 Nov 23
Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates
8:10am
8-K
EX-99.1
eit14yyw8n l6j3h
2 Oct 23
Dawn of the neurotherapeutics era Dr. Jeremy Levin CEO & Chairman
12:15pm
8-K
EX-99.1
rkw b4ud3kyt40474l
4 Aug 23
Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates
9:10am
8-K
EX-99.1
k4cx4ikdwcns48vk4n9
5 May 23
Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates
8:16am
8-K
EX-99.1
dcl0sc2y
1 May 23
Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors
4:17pm
8-K
3wlj5xze1agzm66cx 25
27 Apr 23
Long-term Safety & Efficacy Findings from Soticlestat Open Label Extension Study Presented by Takeda at American Academy of Neurology Annual Meeting
4:43pm
8-K
EX-99.1
7k5qczw1gp6 k5
27 Apr 23
Long-term Safety & Efficacy Findings from Soticlestat Open Label Extension Study Presented by Takeda at American Academy of Neurology Annual Meeting
4:43pm
8-K
EX-99.1
rt4ccj2pl06yyu
8 Nov 22
Ovid Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights
8:41am